- Home
- SPR vs ZLAB Comparison
SPR vs ZLAB Comparison
Compare SPR & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPR
- ZLAB
- Stock Information
- Founded
- SPR 1927
- ZLAB 2013
- Country
- SPR United States
- ZLAB China
- Employees
- SPR N/A
- ZLAB N/A
- Industry
- SPR Military/Government/Technical
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- SPR Industrials
- ZLAB Health Care
- Exchange
- SPR Nasdaq
- ZLAB Nasdaq
- Market Cap
- SPR 3.7B
- ZLAB 3.0B
- IPO Year
- SPR 2006
- ZLAB 2017
- Fundamental
- Price
- SPR $30.70
- ZLAB $27.38
- Analyst Decision
- SPR Hold
- ZLAB Strong Buy
- Analyst Count
- SPR 16
- ZLAB 4
- Target Price
- SPR $35.67
- ZLAB $52.50
- AVG Volume (30 Days)
- SPR 2.1M
- ZLAB 1.2M
- Earning Date
- SPR 10-23-2024
- ZLAB 11-12-2024
- Dividend Yield
- SPR N/A
- ZLAB N/A
- EPS Growth
- SPR N/A
- ZLAB N/A
- EPS
- SPR N/A
- ZLAB N/A
- Revenue
- SPR $6,478,200,000.00
- ZLAB $355,748,000.00
- Revenue This Year
- SPR $2.33
- ZLAB $48.50
- Revenue Next Year
- SPR $27.52
- ZLAB $47.37
- P/E Ratio
- SPR N/A
- ZLAB N/A
- Revenue Growth
- SPR 16.62
- ZLAB 35.01
- 52 Week Low
- SPR $24.39
- ZLAB $13.48
- 52 Week High
- SPR $37.08
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- SPR 40.57
- ZLAB 49.37
- Support Level
- SPR $30.20
- ZLAB $26.47
- Resistance Level
- SPR $31.68
- ZLAB $32.15
- Average True Range (ATR)
- SPR 1.15
- ZLAB 1.36
- MACD
- SPR -0.15
- ZLAB -0.64
- Stochastic Oscillator
- SPR 38.86
- ZLAB 30.81
About SPR Spirit Aerosystems Holdings Inc.
Spirit AeroSystems manufactures aerostructures, particularly fuselages, cockpits, wing sections, engine pylons, and nacelles for commercial and military aircraft. The company was spun out of Boeing in 2005, and the firm is the largest independent supplier of aerostructures for commercial aircraft. Boeing and Airbus are the firm's primary customers—Boeing represented roughly 60% and Airbus roughly 20% of revenue in recent years. The company is highly exposed to Boeing's beleaguered 737 program, which accounts for nearly half the company's revenue.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.